Skip to main content

GSK plc

GLAXF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001131399

No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $70.1M in total; no superinvestor holds it.

Other share classesGSK

Holders of 5% or more of GLAXF

Holders whose latest Schedule 13D or 13G filing reports 5% or more of GSK plc, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of GLAXF
HolderLatest formStakeChangeFirst filedLatest filingFiling
BlackRock, Inc.13G/A8.90%369.6M shares–Mar 7, 20251 filingMar 7, 2025SEC
FMR LLC13G5.80%234.9M sharesNewMay 6, 20261 filingMay 6, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

2 Schedule 13D and 13G filings on GSK plc, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on GLAXF
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 6, 202611:18 AM ETFMR LLCand 1 other13G5.80%234.9M sharesNewMar 31, 2026SEC
Mar 7, 20252:22 PM ETBlackRock, Inc.13G/A8.90%369.6M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

1 notice from officers, directors and other affiliates planning to sell GSK plc shares, newest first.

Form 144 notices for GLAXF
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Aug 20, 202611:19 AM ETMartinez Maria EOfficer44.4K$2.31MAug 20, 2026CHARLES SCHWAB & COSEC